Skip to Content

Pembrolizumab Dosage

Applies to the following strength(s): 25 mg/mL ; 50 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Melanoma - Metastatic

2 mg/kg IV over 30 minutes every 3 weeks

Duration of therapy: Until disease progression or unacceptable toxicity

Use: Treatment of patients with unresectable or metastatic melanoma

Usual Adult Dose for Non-Small Cell Lung Cancer

200 mg IV over 30 minutes every 3 weeks

Duration of therapy: Until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression

Uses:
-For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (Tumor Proportion Score [TPS] 50% or greater) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
-For the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS 1% or greater) as determined by an FDA-approved test, with disease progression on or after platinum containing chemotherapy; patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving this drug.

Usual Adult Dose for Head and Neck Cancer

200 mg IV over 30 minutes every 3 weeks

Duration of therapy: Until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression

Use: For the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy

Renal Dose Adjustments

See DOSE ADJUSTMENTS.

Liver Dose Adjustments

See DOSE ADJUSTMENTS.

Dose Adjustments

WITHHOLD THIS DRUG FOR ANY OF THE FOLLOWING:
-Grade 2 pneumonitis
-Grade 2 or 3 colitis
-Grade 3 or 4 endocrinopathies
-Grade 2 nephritis
-Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 and up to 5 times upper limit of normal (ULN) or total bilirubin greater than 1.5 and up to 3 times ULN
-Any other severe or Grade 3 treatment-related adverse reaction
RESUME THIS DRUG IN PATIENTS WHOSE ADVERSE REACTIONS RECOVER TO GRADE 0 or 1.
PERMANENTLY DISCONTINUE THIS DRUG FOR ANY OF THE FOLLOWING:
-Any life-threatening adverse reaction (excluding endocrinopathies controlled with hormone replacement therapy)
-Grade 3 or 4 pneumonitis or recurrent Grade 2 pneumonitis
-Grade 3 or 4 nephritis
-AST or ALT greater than 5 times ULN or total bilirubin greater than 3 times ULN: For patients with liver metastasis who begin treatment with Grade 2 AST or ALT, if AST or ALT increases by greater than or equal to 50% relative to baseline and lasts for at least 1 week
-Grade 3 or 4 infusion-related reactions
-Inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks
-Persistent Grade 2 or 3 adverse reactions (excluding endocrinopathies controlled with hormone replacement therapy) that do not recover to Grade 0 to 1 within 12 weeks after the last dose of this drug
-Any severe or Grade 3 treatment-related adverse reaction that recurs

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Do not coadminister other drugs through the same infusion line.
-Reconstitute and dilute before use.

Storage requirements:
-Store at room temperature for no more than 4 hours and under refrigeration for no more than 24 hours from time of reconstitution.
-Do not freeze.

General:
-As a therapeutic protein, this drug has immunogenicity potential.

Hide